|
| Thursday, August 21, 2025 |
|
|
Lepu Biopharma (2157.HK) announces 2025 interim results |
| Focusing on the field of tumor treatment, innovative biopharmaceutical company Lepu Biopharma Co., Ltd. (Lepu Biopharma or the Company, stock code: 2157.HK) announced its interim results for the first half of 2025. During the reporting period, the Company's business showed strong growth momentum, achieving profitability for the first time. more info >> |
|
| Thursday, February 23, 2023 |
|
|
Lepu Biopharma and Keymed Jointly Announces Global Exclusive Licence Agreement with AstraZeneca for CMG901 |
| On 23 February, 2023, Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) and Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) today jointly announces a global exclusive licence agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate (ADC). more info >> |
|
| Thursday, September 29, 2022 |
|
|
Lepu Biopharma: Puyouheng (pucotenlimab injection) obtains approval for marketing with a new indication, Breakthrough therapy designation granted by the CDE to MRG003 for the treatment of R/M NPC |
| LEPU BIOPHARMA (2157.HK) announced that its first innovative biological drug, anti-PD-1 antibody - Puyouheng (generic name: pucotenlimab injection) has been approved for marketing by the National Medical Products Administration (NMPA) for the indication of unresectable or metastatic melanomas after the failure of previous systemic therapy. more info >> |
|
| Wednesday, February 23, 2022 |
|
|
Lepu Biopharma Co., Ltd. Successfully Listed on the Main Board of HKEX |
| The biopharmaceutical company focusing on oncology therapeutics - Lepu Biopharma Co., Ltd. ("Lepu Biopharma" or the "Company", stock code: 2157.HK), has successfully listed and commenced dealings on the Main Board of the Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange") today more info >> |
|
| Thursday, February 10, 2022 |
|
|
Lepu Biopharma Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange |
The biopharmaceutical company focusing on oncology therapeutics - Lepu Biopharma Co., Ltd. ("Lepu Biopharma" or the "Company", stock code: 2157), today announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange").
more info >> |
|
|
|
